Phyteau is developing a safe, new class of incretin therapy for diabetes, obesity, NAFLD and related metabolic conditions. Our therapeutics work entirely in the intestines where they trigger key cellular receptors to therapeutically and significantly boost the levels of key metabolic hormones in body, including GLP-1, PYY and CCK. Your own hormones work naturally, safely and powerfully to control blood sugar, appetite, food intake and metabolism. Applications for our therapeutics include pharmaceuticals, targeted medical, diabetic, diet and functional food products, and nutraceuticals. Our approach and technology was developed over the past decade at UCLA, Caltech and Cedars Sinai Medical Center. Phyteau continues to develop new solutions to help the hundreds of millions of people around the world suffering from metabolic diseases. Phyteau highlights: * Plug and Play accelerator, Silicon Valley * RebelBio biotech accelerator in Ireland/UK * Growth Train food accelerator in Denmark * Selected as a Top 500 Global Deeptech Startups for 2019 by Hello Tomorrow * Awarded: Leading Innovators in Metabolic Condition Therapeutics 2019 4th annual Healthcare & Pharmaceutical Awards, hosted by Global Health & Pharma (GHP) magazine